Modafinil

K K Jain MD (Dr. Jain is a consultant in neurology and has no relevant financial relationships to disclose.)
Originally released July 6, 1999; last updated June 25, 2016; expires June 25, 2019

Historical note and terminology

In 1998 the United States Food and Drug Administration approved modafinil as a wake-promoting agent (to improve wakefulness in patients with excessive daytime sleepiness associated with narcolepsy). This was the first time in over 40 years such a drug was approved. In 2010 the European Medicines Agency withdrew the indication of modafinil for the treatment of obstructive sleep apnea, shift-work sleep disorder, and idiopathic hypersomnia.

The content you are trying to view is available only to logged in, current MedLink Neurology subscribers.

If you are a subscriber, please log in.

If you are a former subscriber or have registered before, please log in first and then click select a Service Plan or contact Subscriber Services. Site license users, click the Site License Acces link on the Homepage at an authorized computer.

If you have never registered before, click Learn More about MedLink Neurology  or view available Service Plans.